Jack Hoppin

Jack Hoppin is the co-founder, chairman, and CEO of Ratio Therapeutics, a Boston-based biotech developing targeted radiopharmaceuticals for cancer. A mathematician by training with a PhD in applied mathematics, he previously co-founded the molecular imaging company Invicro and led Konica Minolta Precision Medicine. At Ratio he pairs with scientific co-founder John Babich to build fit-for-purpose radioligand therapies on the company's Trillium pharmacokinetic-modulation and Macropa chelation platforms, backed by investors including Bristol Myers Squibb and a partnership with Novartis.